Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;2(11):27-32.

Neurological complications of biologic therapy in psoriasis: a review

Mark Bechtel  1 , Catherine Sanders, Ann Bechtel
Affiliations

Neurological complications of biologic therapy in psoriasis: a review

Mark Bechtel et al. J Clin Aesthet Dermatol. 2009 Nov.

Abstract

Biologic agents have been a significant advancement in the management of psoriasis. Along with significant clinical improvement, there have been concerns for emerging side effects with the use of biologics. Reports have emerged showing the association between efalizumab and the development of progressive multifocal leukoencephalopathy and other demyelinating disorders. Tumor necrosis factor-alpha inhibitors have been associated with various demyelinating disorders. As such, it is imperative for dermatologists to be well informed regarding how to notify patients about the risks of biologic treatment. Dermatologists must be able to identify the signs and symptoms of neurological complications and recognize when to refer patients to neurologists for diagnostic workup, disease confirmation, and any necessary treatment. This review is a compilation of evidence showing the association between biologic therapy and neurological complications, as well as an overview of the clinical presentation and diagnosis of such diseases.

PubMed Disclaimer

References

    1. Roos KL, Tyler KL. Meningitis, encephalitis, brain abscess, and empyema. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s Principles of Internal Medicine. 17. I and II. New York: The McGraw-Hill Companies, Inc.; 2008. pp. 2634–2635.
    1. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26(3):833–854. - PubMed
    1. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36(8):1047–1052. Epub 2003 Apr 2. - PubMed
    1. Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology. 2006;66(2):262–264. - PubMed
    1. Von Giesen HJ, Neuen-Jacob E, Dörries K, et al. Diagnostic criteria and clinical procedures in HIV-1 associated progressive multifocal leukoencephalopathy. J Neurol Sci. 1997;147(1):63–72. - PubMed

LinkOut - more resources